(Q34808433)

4 August 2017

1 reference

title

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention (English)

1 reference

4 August 2017

0 references

Unwin N

1

1 reference

4 August 2017

Shaw J

series ordinal

2

1 reference

4 August 2017

Zimmet P

series ordinal

3

1 reference

4 August 2017

Alberti KG

series ordinal

4

1 reference

4 August 2017

1 September 2002

1 reference

4 August 2017

1 reference

4 August 2017

19

1 reference

4 August 2017

9

1 reference

4 August 2017

708-723

1 reference

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

4 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Impaired glucose tolerance and fasting hyperglycaemia have different characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Fasting proinsulin concentrations predict the development of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil. The Japanese-Brazilian Diabetes Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Impaired fasting glucose is not a risk factor for atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Sick individuals and sick populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Diabetes and cardiovascular disease. The "common soil" hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance: a dose-response assessment using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Performance of an NIDDM screening questionnaire based on symptoms and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Performance of a predictive model to identify undiagnosed diabetes in a health care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

Transient impaired glucose tolerance in Pima Indians: is it important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2002.00835.X

10.1046/J.1464-5491.2002.00835.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference